Ambulatory high‐dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost‐effective

Abstract

Ambulatory HDMTX administration among an underserved, urban population is safe, feasible, and cost-effective.